Valeant Pharmaceuticals – Has The House Of Cards Finally Collapsed?
Details behind our research that led us to publish multiple warnings on Valeant Pharmaceuticals (VRX) stock, which dropped 50% today.
Historically, the Chinese market has been relatively isolated from international investors, but much is changing there now, making China virtually impossible for the diversified investor to ignore. Earlier this year, CNBC pointed to signs that Chinese regulators may start easing up on their scrutiny of companies after months of clamping down on tech firms. That Read More